# How to Choose Customizable Bioinformatics Software Customizable bioinformatics software lets you change how an analysis works, through parameters, plugins, scripting, or editable source code, while fixed tools lock the workflow so you press a button and accept the output. The rule of thumb: if a result will be published, repeated, validated, or regulated, choose the most customizable tool your team can actually maintain. If you need a one-off answer by Friday, choose the least customizable tool that still answers the question correctly, because every dial you can turn is also a dial you can turn wrongly. This guide walks through the main customizable bioinformatics software options, compares them side by side on the criteria that decide real purchases and real pipelines, works through concrete scenarios, and lists the mistakes that cost labs the most time. ## What "Customizable" Actually Means ![Pyramid of five customization levels from source-code changes at the apex down to parameter settings at the base.](/article-images/illustrations/customizable-bioinformatics-software-customization-levels.webp) Customization is not one property. Software can be customizable in at least five different ways, and tools that advertise themselves as flexible usually excel at only one or two of them. 1. **Parameter customization.** You change thresholds, scoring functions, database choices, or output formats from a settings menu or a command-line flag. Most command-line tools work this way. A pileup program that can emit different output formats is parameter-customizable [1]. 2. **Workflow customization.** You rearrange the order of analysis steps, swap one algorithm for another, or insert your own step. Workflow systems such as KNIME make this explicit. A protein inference study evaluated five inference algorithms combined with three database search engines inside a highly customizable KNIME workflow, which is what allowed the authors to test every combination on four public datasets with defined quality control metrics [2]. 3. **Model or algorithm customization.** You train or reconfigure the underlying statistical or machine learning model. ProsperousPlus does this for protease cleavage site prediction. It ships pre-trained models covering more than 100 proteases, and it also lets you train custom protease-specific models from your own data and then deploy them for large-scale prediction [3]. 4. **Interface and presentation customization.** You change what users see and how they interact with results. DigDig, a standalone Java tool for comparing proteolytic digestion, provides customizable visualizations of sequence coverage, reproducibility, peptide redundancy, and peptide length distributions [4]. expVIP, an RNA-seq visualization platform, lets a lab build a custom web browser around its own species and datasets [5]. 5. **Source-code customization.** You modify the program itself. Fully open-source tools with available source code, such as LIGSIFT for ligand structural alignment, permit this level of change [6]. These levels stack. A tool can expose hundreds of parameters but hide its source code, or ship open code with a rigid interface. When comparing options, ask which of the five levels you actually need. Most labs overestimate their need for level 5 and underestimate their need for level 2. ## The Main Customizable Bioinformatics Software Options Three broad families cover nearly everything you will encounter. Each is described here on its own terms, before any comparison. ### Open-source, scriptable tools and pipelines Open-source tools publish their code and usually run from the command line or from a notebook. The spectrum within this family is wide. At one end sit focused single-purpose utilities such as pileup-hi, a multi-threaded pileup engine (a pileup is a list of nucleotides aligned to each position in a sequence alignment, the raw material for variant calling) designed to scale to alignments with billions of reads and built to be extendable to custom output formats [1]. At the other end sit integrated platforms such as ACVI-Med, an open-source, on-premise platform for variant interpretation that integrates phenotype-aware filtering, ACMG-guided classification (ACMG refers to the American College of Medical Genetics and Genomics framework for classifying variant pathogenicity), and secondary findings detection in a containerized system built for reproducibility [7]. The strengths of this family are transparency and control. You can read the code, pin versions, rerun the exact analysis years later, and fix bugs yourself. In a benchmark against Ion Reporter, a proprietary analysis platform, researchers evaluated eight open-source 16S metagenomics pipelines built on QIIME2 and the SILVA reference database against a commercial mock-community standard. At the species level, single-hypervariable-region open-source pipelines significantly outperformed the other configurations, which shows that a well-configured open pipeline can beat a polished commercial alternative on specific questions [8]. The costs are equally real. Open-source tools assume someone on the team can install dependencies, read error messages, and judge whether a parameter choice makes biological sense. Documentation quality varies enormously, and community support depends on the health of the project. ### Commercial and proprietary platforms Commercial platforms trade flexibility for polish. They bundle installation, support contracts, validated updates, and graphical interfaces that let bench scientists run analyses without a script. For mass spectrometry metabolomics, Compound Discoverer is a commercial package designed specifically for Orbitrap data processing, while MS-DIAL is the open-source counterpart. In a head-to-head evaluation on GC-Orbitrap data for food authentication, Compound Discoverer putatively annotated 52 compounds at Level 2 identification confidence while MS-DIAL annotated 115, and both tools' feature detection was affected by unknown metabolites, background signals, and duplicate features that required careful manual assessment before downstream statistics [9]. Two lessons follow. First, a commercial tool is not automatically more sensitive, and an open tool is not automatically more accurate. Second, in untargeted metabolomics (analysis that profiles all detectable features without targeting known compounds in advance), the tool is only half the battle, because whatever extracts features also hands you artifacts you must clean up yourself. Commercial platforms also appear in structure-based drug discovery. A 2025 review of the covalent docking software landscape describes an ecosystem that now includes open-source, commercial, and web-based platforms supporting binding mode exploration, lead optimization, and structure-based virtual screening, with artificial intelligence and machine learning tools increasingly layered on top [10]. The same review notes a technical ceiling that no license fee removes: many docking tools cannot accurately model the energetics of covalent bond formation, and reliable predictions often require quantum mechanical or semi-empirical QM calculations. Buying the expensive package does not buy the missing physics. ### Web-based and framework platforms The third family sits between the first two. Framework platforms give you a customizable skeleton and let you fill in the domain-specific parts. expVIP is a good example: users deploy it in a virtual machine (a self-contained software computer running on your hardware), point it at public or user-specified RNA-seq datasets, and get a custom web browser for visualizing, sorting, and filtering expression data with minimal bioinformatics knowledge. The developers demonstrated it on polyploid wheat, where a flexible public expression browser grew out of the local deployment [5]. Web-based services, the third subcategory, run someone else's customizable software on someone else's servers. You get customization through forms and upload interfaces but no control over versions, downtime, or data residency. The covalent docking review treats web-based platforms as a distinct class alongside installable open-source and commercial software [10], which reflects how common this delivery model has become. A recent development blurs the boundary between the three families. MN-Suite is an open-source, locally deployable molecular networking toolkit (molecular networking organizes mass spectrometry fragmentation spectra into related clusters to reveal analogues) built through LLM-assisted software engineering under human oversight. It integrates six similarity algorithms and three spectral modes, offers a customizable GUI-based framework for local [preprocessing](/blog/data-analysis/what-is-data-preprocessing), network construction, and visualization, and requires no external server. In an Aconitum dataset, a neutral-loss entropy-similarity strategy produced the highest internal score among tested combinations, and a seed-neighborhood strategy prioritized 26 putative alkaloid analogues for structural confirmation [11]. The notable point for tool selection is the development model: domain experts who could not traditionally write production software used large language models to build exactly the configurable tool they needed, with local deployment for data control. ## Side-by-Side Comparison The table below is the core of the bioinformatics tools comparison. It evaluates the three families plus the framework category against the criteria that decide real choices. Ratings reflect the general character of each family, not every individual product. | Criterion | Open-source CLI/pipeline | Commercial platform | Framework platform | Web-based service | |--|--|--|--|--| | Parameter control | Full, via flags and config files | Curated, menus expose only supported settings | High within the framework's structure | Limited to form fields offered | | Workflow rearrangement | Full with workflow engines | Rare, fixed order with optional steps | High, drag-and-drop or config-driven | Very low | | Algorithm or model training | Full, you own the pipeline | Rare, vendor-controlled models | Often available, e.g. train custom models | Almost never | | Source code access | Yes, usually | No | Depends on license | No | | Ease of first use | Low, requires scripting | High, graphical and guided | Moderate to high | Very high | | Reproducibility | Strong with version pinning and containers | Vendor-dependent, versioned releases help | Strong, e.g. containerized deployments | Weak, server versions change | | Validation and support | Community, variable | Contractual, vendor QC | Mixed, project-dependent | Vendor-managed | | Scalability tuning | Excellent, multi-threading and cluster-native | Bounded by license and vendor roadmap | Good, often container- or VM-based | None, server-side limits | | Typical cost structure | Free licenses, staff time and hardware | Subscription or license fees | Mostly free, hosting costs | Subscription or per-analysis fees | | Auditability of results | Full, every step inspectable | Partial, vendor documentation only | High for local deployments | Low | | Data control | Full, runs locally | Usually local, sometimes cloud | Full for local deployments | Data leaves your control | Two of these rows deserve emphasis because they drive more decisions than the rest. Reproducibility is the property that separates a publishable analysis from a one-off screenshot. Containerized systems, in which software and all dependencies ship in a single portable unit, make reproducibility practical, which is exactly why an open variant interpretation platform was built as a containerized system for deployment across diverse institutional environments [7]. Scalability tuning matters when data volume grows. The pileup example is concrete: a scalable, customizable pileup engine reached up to 13 times the speed of the de facto standard samtools mpileup while remaining binary-equivalent to its default output, and it was built specifically because the older tool could not keep up with modern sequencing throughput [1]. Customization and performance are not opposites. Often the customizable rewrite is the fast one. ## Comparing Tools on the Criteria That Decide Real Choices Feature lists make tools look interchangeable. They are not. These are the criteria that actually separate options once you have a shortlist, with published examples of each criterion in action. ### Analytical performance and its context-dependence Performance numbers are only meaningful relative to a task, a dataset, and a reference standard. The 16S metagenomics evaluation benchmarked against a commercial mock community characterized by shotgun sequencing, used Poisson regression modeling on read counts, and found that the choice of denoising algorithm (the statistical step that distinguishes true sequence variants from sequencing errors) significantly affected alpha diversity calculations across all configurations [8]. The practical implication for any bioinformatics tools comparison is that you should benchmark candidate tools on your own data type, not on the vendor's demo dataset. The metabolomics comparison makes the same point from the commercial side. The two GC-Orbitrap tools differed substantially in how many compounds they putatively annotated at Level 2 confidence, and both produced feature tables contaminated by background signals and duplicates that had to be assessed before [multivariate analysis](/blog/data-analysis/multivariate-analysis) was trustworthy [9]. A tool that extracts more features is not automatically better. A tool that makes artifacts easy to inspect may serve you better than one that hides them behind a clean interface. ### Output agreement and equivalence When you replace an established tool, check whether outputs match. The pileup benchmark explicitly verified binary equivalence of the new engine's default output against the standard tool across benchmark conditions [1]. That single sentence in a methods paper is what allows a lab to adopt the faster tool without revalidating every downstream script. When you evaluate any replacement, demand that kind of equivalence statement or generate one yourself on a small reference dataset. ### Stability of results across conditions A tool that gives a different answer when the input database grows is a liability in multi-sample studies. The protein inference study (inference is the step that assembles identified peptides into a defensible list of proteins) evaluated five inference tools against three search engines across four datasets of varying complexity and found that results for complex samples differed both in the number of reported protein groups and in the actual composition of those groups, and that robustness to database complexity depended strongly on the applied inference algorithm [2]. The customizable KNIME workflow was what made this systematic testing possible. That is customization paying a dividend: the flexible framework enabled the comparison itself. ### Match between customization level and team skill Be honest about your team. expVIP was designed so that users with minimal bioinformatics knowledge could analyze RNA-seq data through a virtual machine and an intuitive interface, and it still produced a functional public expression browser for a polyploid crop [5]. ACVI-Med similarly targets accessibility, enabling users without extensive bioinformatics expertise to interpret variants from VCF (Variant Call Format) files through phenotype-driven filtering and interactive visualization [7]. These tools show that customization and usability are compatible when the customizable layer is wrapped in a good interface. If nobody on your team can use a terminal, an open-source CLI tool is the wrong choice regardless of its quality, unless you can hire or borrow the expertise. ### Deployment model and data control Where the software runs decides who sees your data and whether the analysis survives a vendor's shutdown. Locally deployable open-source toolkits exist precisely because some labs need server-independent workflows with full data control [11]. On-premise platforms with containerized deployment support institutions that cannot send genomic data to external servers [7]. Web-based services invert this, trading control for convenience. For clinical genomics, controlled natural product research, or any regulated context, local deployment usually wins. For a literature survey or a teaching exercise, a web service often wins. ### Licensing and who may use the software Open does not always mean unrestricted. LIGSIFT, an open-source shape-based ligand alignment and virtual screening tool that uses Gaussian molecular shape overlay with a size-independent, statistically grounded scoring function rather than the size-dependent Tanimoto coefficient common in commercial and free tools alike, distributes source code freely to academic users specifically [6]. Read the license before you build a core workflow on a tool. Academic-only licenses, field-of-use restrictions, and attribution requirements all surface at the worst possible time, usually during a technology transfer discussion. ## Worked Scenarios Abstract criteria become clear in concrete situations. Four scenarios cover the most common decision patterns. ### Scenario 1: A clinical genomics lab needs variant interpretation A hospital molecular lab runs whole genome and [exome sequencing](/blog/guides/exome-sequencing) and needs to move variant interpretation (turning a VCF file of thousands of variants into a short list of clinically actionable candidates) from ad hoc spreadsheets to a defensible system. Requirements: phenotype-aware filtering, ACMG-guided classification, secondary findings detection, reproducibility, and deployment within the hospital network. The best customizable bioinformatics software here is an open-source, containerized, on-premise platform. ACVI-Med matches these requirements directly: it integrates phenotype-aware filtering, ACMG-guided variant classification aligned with the ACMG Secondary Findings v3.2 recommendations, real-time curated knowledge bases, and interactive visualization in a containerized system designed for reproducibility across institutional environments [7]. A commercial interpretation suite would also work and would come with vendor validation documentation, which matters under clinical quality systems. The decisive question is whether the lab needs to inspect and modify the classification logic. If yes, open source. If the lab needs vendor support for accreditation paperwork more than it needs code access, commercial may fit better. Either way, the customizable filtering logic is what allows the lab to encode its own clinical policies rather than inherit someone else's. ### Scenario 2: A metabolomics core is choosing between an open tool and a commercial one A food authentication lab processes GC-Orbitrap untargeted metabolomics data and must pick processing software for feature extraction, annotation, and marker discovery. The published head-to-head gives them a starting template rather than an answer. Both the open MS-DIAL and the commercial Compound Discoverer supported the discrimination and marker identification goal, but they differed in annotation counts (115 versus 52 compounds at Level 2) and both required careful manual assessment of unknowns, background signals, and duplicate features before downstream statistics [9]. The right move is to run both tools on a shared pilot dataset, apply the same manual curation criteria, and see which feature table leads to more defensible markers. The published comparison shows that either can work and that neither eliminates the curation burden. ### Scenario 3: A natural products group needs molecular networking without a server A chemistry lab studies alkaloids in Aconitum and wants molecular networking with the ability to choose among similarity algorithms and spectral modes, but the institution restricts data upload to external services. A locally deployable, GUI-based, customizable toolkit fits. MN-Suite offers six similarity algorithms and three spectral modes (MS2, neutral loss, and a hybrid), runs locally, and in the published case prioritized 26 putative alkaloid analogues through a diagnostic-ion and neutral-loss filtering strategy combined with a seed-neighborhood approach [11]. The customizability here is not decorative. Testing which algorithm-mode combination scores best on your own data is the whole method, and a fixed tool would deny you that test. ### Scenario 4: A proteomics lab needs to standardize a multi-step analysis A proteomics facility runs data from three search engines and wants consistent protein-level reporting. The relevant lesson comes from the inference evaluation: five inference tools behaved differently on complex samples, and results depended on the interaction of search engine, algorithm, and dataset [2]. Building the comparison inside a customizable workflow system such as KNIME let the authors define quality control metrics and run every combination systematically. The scenario's lesson generalizes: when several defensible algorithms exist for one step, do not pick by reputation. Build the step into a customizable workflow, run the combinations on your data, and pick with metrics. ### Scenario 5: A high-volume clinical sequencing center hits a performance wall A cancer screening program generates alignments with billions of reads and its pileup step cannot keep pace with clinical turnaround needs. This is the case where a customizable, scalable rewrite beats both the legacy default and the commercial alternative. pileup-hi was created for exactly this bottleneck, delivered multi-threaded performance up to 13 times faster than samtools mpileup, 3.2 times faster than sambamba mpileup, and up to 8 times faster than perbase base-depth, while producing default output with binary equivalence to the standard format and remaining extendable to custom output formats [1]. When throughput, not features, is the constraint, evaluate tools on measured speed against your data volume and on output compatibility with your downstream scripts. ## Customizable Bioinformatics Software Pros and Cons A balanced view of the pros and cons, drawn from the evidence above, prevents both of the common extremes: fetishizing open source and defaulting to whatever has the best sales team. **Pros of highly customizable software:** - Full control over parameters, algorithms, and workflow order, which enables systematic benchmarking such as the multi-algorithm inference study [2] - Reproducibility through version pinning, containers, and local deployment, which underpins clinical-grade platforms [7] and server-independent toolkits [11] - Transparency, because every step is inspectable, which is essential when feature extraction injects artifacts that must be assessed manually [9] - Adaptability to novel questions, such as training custom protease-specific prediction models from user-provided data [3] - Performance headroom, since customizable rewrites can dramatically outperform established defaults under modern workloads [1] **Cons of highly customizable software:** - Skill requirements. Scriptable tools assume competence that many bench labs do not have in-house, which is why interface-focused platforms were built for users with minimal bioinformatics knowledge [5] - Support fragility. Community-maintained tools can stagnate, and the person who understood the pipeline may leave - Responsibility for errors. When you configure the pipeline, misconfiguration is yours, and a denoising algorithm choice alone measurably shifts diversity results [8] - Time cost. Benchmarking five inference tools across three search engines and four datasets is real work, and it is the price of a defensible choice [2] - Documentation gaps that force you to read source code to understand behavior **Pros of fixed or lightly customizable tools:** speed to first result, vendor accountability, guided interfaces, and bundled validation. **Cons:** you inherit the vendor's analytical decisions, you cannot rearrange steps or train models, reproducibility depends on vendor releases, and, in some domains, no license fee fixes the underlying algorithmic limits, as the covalent docking review makes clear about the QM-level energetics that most docking tools cannot model [10]. ## Common Mistakes and Limitations These are the errors that cost labs the most time, in rough order of frequency. 1. **Choosing by feature count instead of by task fit.** The tool that annotates more compounds is not the better tool if its features include duplicates and background signals you cannot practically curate [9]. Define your decision criterion (defensible markers, stable protein groups, clinically actionable variants) before you open a single interface. 2. **Benchmarking on the wrong data.** Vendor demo datasets are curated to flatter the vendor. The 16S evaluation produced its useful conclusions only by benchmarking against an independently characterized mock community standard [8]. Use your own matrix, your own instrument, your own species. 3. **Ignoring output compatibility.** A faster tool that emits a different format invalidates every downstream script. The pileup benchmark's binary-equivalence claim is the model to demand [1]. If a candidate tool offers no equivalence statement, generate your own on a reference file before adoption. 4. **Assuming customization equals quality.** Access to parameters means access to bad parameters. Each published comparison found that reasonable-looking configurations produced materially different results [2][8]. Customization raises the ceiling and lowers the floor. 5. **Underestimating maintenance.** The true cost of a customizable pipeline is not the install, it is the next five years of dependency updates, database version changes, and staff turnover. Containerization addresses part of this, which is why reproducibility-focused projects adopt it [7], but a container does not read the literature for you when the ACMG recommendations update. 6. **Treating a benchmark result as a permanent ranking.** Software evolves. A review of the covalent docking landscape describes a field where open-source, commercial, and web-based options are multiplying and AI-assisted tools are entering rapidly [10]. Any tool ranking has a short shelf life. Revisit your shortlist at least annually. 7. **Forgetting the statistical step matters as much as the software.** In the 16S comparison, the denoising algorithm choice significantly affected alpha diversity across every configuration tested [8]. Pipeline-level choices inside a tool can outweigh the choice between tools. **Limitations of this guide.** The comparisons cited here come from specific data types, instruments, and years. A metabolomics result on GC-Orbitrap thyme data does not transfer to LC-MS [plasma proteomics](/knowledge/bioinformatics/plasma-proteomics-from-sample-collection-to-biomarker-discovery), and a 16S benchmark on one platform does not settle every amplicon question. Published head-to-head studies cover a small fraction of available software, and most tools have no independent benchmark at all. Where no benchmark exists, the workflow-engine approach, running candidate tools side by side on your own data with defined metrics, is the honest substitute [2]. For clinical diagnostics, final analytic and clinical validation belongs with the laboratory director and qualified professionals under the applicable quality frameworks, not with a software default. ## A Practical Selection Checklist ![Decision path asking about code access, vendor support, and data upload rules to pick a software family.](/article-images/illustrations/customizable-bioinformatics-software-which-family.webp) Work through this list before committing to any of the customizable bioinformatics software options you are considering. 1. Write down the decision the software must support (a marker list, a protein group table, a variant classification). If you cannot state it in one sentence, you are not ready to choose. 2. Decide which customization level you need: parameters, workflow, models, interface, or source code. 3. Inventory your team's actual skills, including who maintains the pipeline when the person who built it leaves. 4. Shortlist two or three candidates from at least two families. A commercial alternative on the shortlist keeps the open-source candidates honest, and vice versa. 5. Benchmark on your own data against an appropriate reference standard, with metrics you defined in advance. 6. Check output equivalence against any tool you are replacing, down to file format and values where feasible. 7. Read the license, including who may use the software and whether your intended use (commercial screening, clinical reporting, redistribution) is permitted. 8. Verify reproducibility mechanics: version pinning, container availability, and whether the tool records its own settings in outputs. 9. Estimate total cost of ownership honestly: license fees plus hardware plus the staff time that open-source tools convert from purchase price into labor. 10. Set a review date. Software landscapes shift quickly enough that this list deserves an annual rerun. ## Frequently Asked Questions ### What counts as customizable bioinformatics software? Any analysis software whose behavior you can meaningfully change counts, at five levels: parameters you can set, workflow steps you can rearrange, models you can train, interfaces you can adapt, and source code you can modify. A tool qualifies as customizable if it operates at your required level, and many polished tools are customizable in one dimension while rigid in the others. ### Is open-source always the best bioinformatics software? No. Open-source tools won on species-level taxonomic profiling in one 16S benchmark and annotated more compounds than a commercial package in one metabolomics comparison, but the same studies show that results depend far more on configuration, data type, and curation than on the license. Choose open source when transparency, code access, or local deployment are requirements, and choose commercial when contractual support and validated updates are. ### Do I need to know how to program to use customizable tools? Not necessarily, because customization level varies. Platforms such as expVIP and ACVI-Med expose substantial customization, including phenotype-driven filtering and configurable browsers, through graphical interfaces designed for users without extensive bioinformatics expertise. You do need programming or scripting skills for parameter-level and source-code-level customization, and someone on the team or on call needs those skills for any pipeline you expect to maintain. ### How do I run a fair bioinformatics tools comparison on my own data? Fix three things before running anything: a reference standard appropriate to your data (such as a characterized mock community for microbiome work), a small set of metrics defined in advance, and identical inputs across tools. Then test all candidate configurations systematically, ideally inside a customizable workflow system so that every combination runs the same way, and inspect intermediate outputs, not just final tables, because artifacts introduced at feature detection propagate into every downstream statistic. ### Can AI tools help me build a custom pipeline? Yes, and there is a published precedent. MN-Suite was developed through LLM-assisted software engineering under human oversight, producing an open-source, locally deployable molecular networking toolkit with multiple similarity algorithms and a customizable GUI. The realistic framing is that AI assistance lowers the barrier for domain experts to build specialized tools, with human review of the code and validation of the outputs remaining essential. ### What hardware and setup do customizable tools typically require? It depends on the deployment model. Command-line tools benefit from multi-threaded hardware and can scale to very large datasets, as demonstrated by a pileup engine built for alignments with billions of reads. Framework platforms commonly ship as containers or virtual machines that run on ordinary lab servers or workstations. Locally deployable GUI toolkits are designed to run without dedicated servers. Check whether the tool publishes minimum requirements and, for clinical or regulated use, whether your institution's infrastructure policies permit the deployment model. ## Sources 1. [Pileup-hi: an ultra-high-throughput, customizable alignment pileup program for large datasets.](https://pubmed.ncbi.nlm.nih.gov/42804722/) 2. [In-depth analysis of protein inference algorithms using multiple search engines and well-defined metrics.](https://pubmed.ncbi.nlm.nih.gov/27498275/) 3. [ProsperousPlus: A Bioinformatics Workflow for Protease Substrate Cleavage Site Prediction and Model Construction Utilizing Machine Learning.](https://pubmed.ncbi.nlm.nih.gov/42895448/) 4. [DigDig: A Software for In-Depth Analysis and Comparison of Proteolytic Digestion.](https://pubmed.ncbi.nlm.nih.gov/40998310/) 5. [expVIP: a Customizable RNA-seq Data Analysis and Visualization Platform.](https://pubmed.ncbi.nlm.nih.gov/26869702/) 6. [LIGSIFT: an open-source tool for ligand structural alignment and virtual screening.](https://pubmed.ncbi.nlm.nih.gov/25336501/) 7. [ACVI-Med, an open source variant interpretation tool for medical genomics.](https://pubmed.ncbi.nlm.nih.gov/41781882/) 8. [Evaluating 16S metagenomics data analysis pipelines using an Ion Torrent sequencer for human gut microbiome research.](https://pubmed.ncbi.nlm.nih.gov/42919172/) 9. [Comparison of data processing strategies using commercial vs. open-source software in GC-Orbitrap-HRMS untargeted metabolomics analysis for food authentication: thyme geographical differentiation and marker identification as a case study.](https://pubmed.ncbi.nlm.nih.gov/38805060/) 10. [The covalent docking software landscape: features and applications in drug design.](https://pubmed.ncbi.nlm.nih.gov/41470049/) 11. [LLM-Assisted Development of a Locally Deployable Molecular Networking Toolkit: Enabling Customizable Analysis in Natural Products.](https://pubmed.ncbi.nlm.nih.gov/42487283/)